Literature DB >> 11062734

Reduced invasiveness and metastasis of Chinese hamster ovary cells transfected with human interleukin-17 gene.

N Hirahara1, Y Nio, S Sasaki, M Takamura, C Iguchi, M Dong, K Yamasawa, M Itakura, K Tamura.   

Abstract

Human IL-17 (hIL-17) stimulates epithelial, endothelial, fibroblastic cells and macrophages to secrete various cytokines. The present study was designed to assess the effects of the transfection of the hIL-17 gene in Chinese hamster ovary (CHO) cells. A complementary DNA (cDNA)-encoding hIL-17 was obtained by polymerase chain reaction (PCR) amplification from human CD4+ T-cell cDNA and inserted into the plasmid pRc/CMV to construct an expression vector for hIL-17. CHO cells were transduced with hIL-17 DNA-carrying cytomegalovirus (CMV)-based retroviral vectors. A clone with a high mRNA expression of hIL-17 (CHO/IL-17) was selected by Northem blotting. There was no significant difference in the in vitro growth of cells among parent CHO cells, vector-only transfected cells (CHO/neo) and CHO/IL-17 cells. A Matrigel invasion chamber assay, however, demonstrated significantly lower invasiveness by CHO/IL-17 cells than by either the parent CHO or the CHO/neo cells. There was no difference in the in vivo growth among the cells, when subcutaneously transplanted into nude mice. When injected into the tail vein, however, the number of metastatic nodules in the lungs of CHO/IL-17-injected mice was significantly smaller than that of CHO- or CHO/neo-injected mice. Furthermore, NK activity of spleen cells was significantly higher in nude mice transplanted with CHO/IL-17 cells than in mice transplanted with parent CHO or CHO/neo cells. In conclusion, the hIL-17-gene-transfected CHO cells showed a significantly lower metastatic potential to the lung by directly modulating the invasiveness and metastasis of CHO cells as well as by enhancing NK activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062734

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist.

Authors:  Susumu Nakae; Shinobu Saijo; Reiko Horai; Katsuko Sudo; Shigeo Mori; Yoichiro Iwakura
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

2.  IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis.

Authors:  M C Honorati; S Neri; L Cattini; A Facchini
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 3.  The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease.

Authors:  B Afzali; G Lombardi; R I Lechler; G M Lord
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 4.  Interleukin-17: a promoter in colorectal cancer progression.

Authors:  Dang Wu; Pin Wu; Qi Huang; Yang Liu; Jun Ye; Jian Huang
Journal:  Clin Dev Immunol       Date:  2013-12-07

5.  Effect of IL-17 in the development of colon cancer in mice.

Authors:  Lijuan Yang; Hao Liu; Lili Zhang; Jie Hu; Haixia Chen; Lei Wang; Xiaolin Yin; Quanhai Li; Yixin Qi
Journal:  Oncol Lett       Date:  2016-10-31       Impact factor: 2.967

6.  IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines.

Authors:  XingWu Zhu; Lori A Mulcahy; Rabab A A Mohammed; Andrew H S Lee; Hester A Franks; Laura Kilpatrick; Acelya Yilmazer; E Claire Paish; Ian O Ellis; Poulam M Patel; Andrew M Jackson
Journal:  Breast Cancer Res       Date:  2008-11-17       Impact factor: 6.466

7.  Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy.

Authors:  Monika Bilska; Anna Pawłowska; Ewelina Zakrzewska; Agata Chudzik; Dorota Suszczyk; Marek Gogacz; Iwona Wertel
Journal:  J Oncol       Date:  2020-02-21       Impact factor: 4.375

Review 8.  MAIT Cells: Partners or Enemies in Cancer Immunotherapy?

Authors:  Dasha T Cogswell; Laurent Gapin; Heather M Tobin; Martin D McCarter; Richard P Tobin
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.